Vanda’s drug for rare disorder meets main trial goal

Vanda Pharmaceuticals Inc said a late-stage trial of its drug for treating a rare disorder affecting blind people met the main goal of showing improvement over a placebo.

The drug, tasimelteon, was being tested as a treatment for non-24-hour disorder, a rare and chronic circadian rhythm disorder that affects a majority of blind people, Vanda said.

(Reporting by Esha Dey in Bangalore)



Provided by ArmMed Media